| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 59.2 | 48.8 | 46.5 |
| Other income | 1.8 | 2.1 | 0.7 |
| Total income | 61.0 | 50.9 | 47.2 |
| Profit before exceptional items & tax | 12.7 | 10.3 | 8.1 |
| Profit before tax | 12.7 | 10.3 | 8.1 |
| Net profit | 10.9 | 6.7 | 6.9 |
| Operating margin | 20.8% | 20.2% | 17.2% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +58.00% |
|---|---|
| Net profit, quarter on quarter | +62.70% |
| Revenue, year on year | +27.30% |
| Operating profit, year on year | +47.30% |
| Operating profit, quarter on quarter | +32.90% |
BSE results filing, NSE: TITANBIO. Figures extracted from the filing.
Titan Biotech Ltd: key numbers
- Share price
- ₹398.70
- Market cap
- ₹1,647 Cr
- Revenue (annual)
- ₹206.2 Cr
- Net profit (annual)
- ₹29.89 Cr
- P/E (TTM)
- 48.6×Sector 37.5×
- Promoter holding
- 55.78%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Titan Biotech Ltd
All →Titan Biotech Other Announcement
Titan Biotech has dispatched letters to shareholders with unregistered emails, providing web links to access the FY 2025-26 Annual Report and 34th AGM Notice.
Titan Biotech Annual Report
Titan Biotech filed its 34th Annual Report and AGM Notice for the financial year 2025-26. The AGM is scheduled for September 29, 2026.
Titan Biotech Dividend
Titan Biotech Limited has fixed September 22, 2026, as the record date for a final dividend of ₹0.50 per share. The payout remains subject to shareholder approval.
Titan Biotech Annual General Meeting
Titan Biotech Limited will hold its 34th Annual General Meeting on September 29, 2026. The company set September 22, 2026, as the record date for final dividend eligibility.
Titan Biotech Bonus Issue
Titan Biotech Limited approved a 1:4 bonus issue and increased its authorised share capital to Rs. 10.40 Crore. The bonus issue is subject to shareholder approval at the upcoming AGM.
- Value
- ₹2.07 Cr
Titan Biotech Q4 FY26 Results: Net Profit ₹6.7 Cr, Up 67.5% YoY
Titan Biotech Ltd reported revenue from operations of ₹48.8 Cr (+38.6% YoY) and net profit of ₹6.7 Cr (+67.5% YoY) for Q4 FY26.
- Key figure
- Net profit ₹6.7 Cr · +67.5% YoY